Search

Objective: To investigate the effects of pregabalin combined with serratus anterior plane block (SAPB) on sleep quality and serum inflammatory factors in patients after thoracoscopic radical resection of lung cancer. Methods: The collection period of cases was from March 2019 to July 2020. 60 patients who met the requirements after thoracoscopic radical resection of lung cancer were screened and divided into the control group (n=30) and the study group (n= 30). Both groups were given SAPB, followed by intravenous patient-controlled analgesia. The control group was given a placebo. The study group was given pregabalin 150 mg 2 hours before surgery and 75 mg pregabalin on the second day after surgery. The sedative and analgesic effects, sleep quality, serum inflammatory factors, anxiety, vital signs and adverse reactions were compared between the two groups. Results: The visual pain analogue scale (VAS) of the study group was lower than that of the control group at 12 h, 24 h, and 48 h after the operation, and the Ramsay score was higher than that of the control group (P<0.05). The 48h postoperative state-trait anxiety scale (STAI) and Pittsburgh Sleep Quality Index (PSQI) scores of the study group were lower than those of the control group (P<0.05). Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP) in the study group were lower than those in the control group at 24 h and 48 h after surgery (P<0.05). The heart rate (HR) of the study group was lower than that of the control group at 4 h, 24 h, and 48 h after the operation, and the systolic blood pressure (SBP) and diastolic blood pressure (DBP) were higher than those of the control group (P<0.05). There was no statistical difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Pregabalin combined with SAPB in patients after thoracoscopic radical resection of lung cancer can maintain the patient's vital signs, obtain good analgesic and sedative effects, improve the patient's sleep quality, reduce their anxiety, and reduce serum inflammation. The level of sex factors is safe. [ABSTRACT FROM AUTHOR]

Objective: To investigate the effect of high mobility group protein 1 (HMGB1) antagonist BoxA via tail vein injection on the improvement of clinical signs and anti-inflammatory effects in a rat model of bacterial meningitis (BM). Methods: Male Sprague-Dawley (SD) rats were used and the normal rats were set as the control group (n=20). Another sixty rats were injected with Es- cherichia coli (DH5α1× 107 CFU/mL) to establish BM rat model and then were randomly divided into two groups (n=30): after anesthesia one group received intravenous BoxA (BoxA group), the other one received PBS injection as placebo (Vehicle group). Three days after model establishment, the clinical index of each group and pathophysiological parameters (intracranial pressure and CSF white blood cells (WBC) count) were evaluated, Enzyme-linked immunosorbent assay (ELISA) method were used to detect the relative serum HMGB1 content, Evans blue staining were used to observe the blood-brain barrier (BBB) permeability, immunofluorescence staining were used to detect the expression level of cerebral inflammation cytokines (IL-1β and TNF-α). Results: Compared with Control group, clinical indicators, intracranial pressure, WBC count and serum HMGB1 content in Vehicle group has significantly increased (P<0.05). These changes were partially reduced in the BoxA group compared to the Vehicle group (P<0.05). In addition, Vehicle group showed increased EB leakage and increased expression of inflammatory factors (IL-1β and TNF-α) than Control group (P<0.05). These changes were also partially adjusted in the BoxA group compared to the Vehicle group (P<0.05). Conclusion: Tail vein injection of HMGB1's inhibitor BoxA can down-regulate HMGB1 expression and alleviate the clinical symptoms and inflammatory responses in BM rats. [ABSTRACT FROM AUTHOR]